Benzylpiperazine

Benzylpiperazine, often abbreviated as BZP, is a psychoactive drug that acts as a stimulant. It is chemically related to amphetamines and methylenedioxymethamphetamine (MDMA). BZP was first synthesized in the 1940s and was initially investigated as an antidepressant, though it proved ineffective for that purpose. In later years, it gained popularity as a recreational drug, often sold as a substitute for MDMA or as a party pill.

The effects of BZP are dose-dependent and can include increased alertness, euphoria, and a sense of increased energy. However, it can also cause adverse effects such as anxiety, nausea, vomiting, headaches, and in some cases, more severe psychological reactions. The stimulant properties are due to its action on the central nervous system, particularly by increasing the release of dopamine and norepinephrine.

BZP is typically taken orally, often in tablet or capsule form. Its legal status varies significantly worldwide. Many countries have classified it as a controlled substance due to its potential for abuse and associated health risks. In some regions, it was initially marketed as a legal high, but has since been banned or regulated in most places. Research into its long-term effects and specific pharmacological mechanisms is ongoing.